Sign In to Request a Protocol
Sign In to Request a Protocol

Vesugen (Lys-Glu-Asp) (20 mg Vial) Protocol

  • Table of Contents

Vesugen Chart, Vitality Labs

Vesugen is dosed at 500 mcg–2 mg daily via subcutaneous Application in educational protocols. A Lys-Glu-Asp reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for research and educational use only.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
  • Typical daily range: 500–2000 mcg once daily (gradual titration).
  • Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after Preparation, refrigerate at 2–8 °C (35.6–46.4 °F) ; avoid freeze–thaw cycles.

Vesugen (Lys-Glu-Asp, also known as KED) is a tripeptide bioregulator synthesized at the Saint Petersburg Institute of Bioregulation and Gerontology. Research suggests it may support vascular endothelial cell proliferation through epigenetic regulation of Ki-67 gene expression. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

  • Research Information Guide

Educational guide for Preparation and daily dosing

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

WeekDaily Dose (mcg)Units (per Procedure ) (mL)
Week 1500 mcg (0.5 mg)7.5 units (0.075 mL)
Week 21000 mcg (1.0 mg)15 units (0.15 mL)
Week 31500 mcg (1.5 mg)22.5 units (0.225 mL)
Weeks 4–8+1500–2000 mcg (1.5–2.0 mg)22.5–30 units (0.225–0.30 mL)

Frequency: Usage Method once daily subcutaneously. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Note that Week 1 dosing falls at 7.5 units; a 50-unit syringe with 0.5-unit graduations improves accuracy.

Preparation Steps

  • 1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2. Usage Method slowly down the vial wall; avoid foaming.
  • 3. Gently swirl/roll until dissolved (do not shake).
  • 4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Research Requirements

Plan based on an 8–16 week daily protocol with gradual titration (targeting ~1500 mcg/day maintenance).

  • 8 weeks (~84 mg total) ≈ 5 vials
  • 8 weeks (~84 mg total) ≈ 5 vials
  • 12 weeks (~126 mg total) ≈ 7 vials
  • 16 weeks (~168 mg total) ≈ 9 vials
  • Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for Preparation.
  • 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
  • 12 weeks (7 vials): 21 mL→ 3 × 10 mL bottles
  • 16 weeks (9 vials): 27 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the Usage Method site each day
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
  • Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support vascular endothelial function and cellular renewal over time
  • Schedule: Daily subcutaneous Usage Method for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 500–2000 mcg daily with gradual titration.
  • Preparation: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
  • Research Overview

Suggested daily titration approach.

  • Start : 500 mcg daily; increase by ~500 mcg weekly as tolerated.
  • Target: 1500–2000 mcg daily by Weeks 3–8+.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Any consistent time; rotate Usage Method sites.
  • Material Handling Considerations

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate Usage Method sites (abdomen, thighs, upper arms) to reduce local irritation
  • Usage Method slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • How This Works

Vesugen (KED) is a tripeptide derived from amino acids associated with vascular wall proteins. Research indicates it may support vascular endothelial cell proliferation by modulating the expression of Ki-67, a protein closely associated with cell division. The peptide is hypothesized to interact with promoter regions of the Ki-67 gene, potentially influencing epigenetic regulation. Additional studies suggest Vesugen may normalize endothelin-1 expression and increase sirtuin-1 (SIRT-1) expression in vascular endothelial cells.

  • Potential Benefits & Side Effects

Observations from preclinical and cell culture research.

  • May support vascular endothelial cell proliferation and renewal through Ki-67 gene regulation
  • Research suggests potential neuroprotective properties; oral application improved memory and attention in elderly individuals with functional CNS disorders
  • May restore synaptic plasticity in in vitro models of Alzheimer’s disease
  • Generally well tolerated in reported studies; occasional mild Usage Method-site reactions (redness/itch) may occur with subcutaneous administration.
  • Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, heart-healthy diet rich in antioxidants and omega-3 fatty acids.
  • Combine regular cardiovascular exercise to reinforce vascular adaptations.
  • Prioritize sleep and stress management to support recovery and cellular renewal.
  • Usage Method Technique

General subcutaneous guidance from clinical best-practice resources

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue
  • Do not aspirate for subcutaneous Usage Method; Usage Method slowly and steadily
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy
  • Recommended Source
We recommend Vitality Labs Peptides for high-purity Vesugen (20 mg).

Why Vitality Labs Peptides?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Shop at Vitality Labs
  • Important Note

This content is for educational purposes only and is not medical advice.

  • References

Bull Exp Biol Med (2016)

— Short Peptides Regulate Gene Expression (Khavinson et al.)
More Info

Adv Gerontol (2014)

— Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging
More Info

Molecules (2021)

— Peptide Regulation of Gene Expression: A Systematic Review (MDPI)
More Info

Adv Gerontol (2016)

— Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis
More Info

Bull Exp Biol Med (2021)

— Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer’s Disease
More Info

Bull Exp Biol Med (2017)

— Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer’s Disease
More Info

Int J Mol Sci (2022)

— Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease
More Info

Pharmaceuticals (2021)

— Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease
More Info

DailyMed

— Bacteriostatic Water Usage Method, solution (FDA labeling)

More Info

PMC (2024)

— Practical advice in the development of a lyophilized protein drug product

More Info

MedlinePlus

— Subcutaneous (SQ) Usage Method: technique and site guidance
More Info

NCBI Bookshelf

— Best practices for Usage Method (WHO guidelines)

More Info

CDC

— Vaccine administration: subcutaneous Usage Method technique

More Info

Biogerontology (2010)

— Peptide bioregulation of aging: Results and prospects (Anisimov & Khavinson)
More Info

Stem Cell Rev Rep (2020)

— Peptide Regulation of Cell Differentiation
More Info

Vitality Labs Peptides

— Vesugen (20 mg) product page (quality and batch documentation)
More Info